Please ensure Javascript is enabled for purposes of website accessibility

Why Guardant Health Stock Is Sinking Today

By Keith Speights - Feb 25, 2021 at 11:34AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The company reported disappointing Q4 results.

What happened

Shares of Guardant Health (GH 5.81%) were sinking 7.2% as of 11:08 a.m. EST on Thursday. The decline came after the company reported its fourth-quarter results following the market close on Wednesday.

Guardant Health announced Q4 revenue of $78.3 million, up 25% year over year and higher than the average analyst estimate of $76.7 million. However, the company's Q4 net loss of $93.7 million, or $0.94 per share, reflected deterioration from the prior-year period and was worse than the Wall Street consensus net loss of $0.57 per share.

$1 bill folded into an arrow pointing down

Image source: Getty Images.

So what

It's not unusual for growth stocks like Guardant Health to fall quite a bit after missing a quarterly earnings estimate. The company's valuation depends on investors' perceptions of its growth prospects. Failing to meet analysts' expectations negatively impacts those perceptions.

However, it's best not to focus too much on underperformance in one quarter. The most important takeaway from Guardant Health's Q4 update is that its liquid biopsy products continue to enjoy strong demand.

It's true, though, that the company expects its growth rate to slow. Guardant Health projects full-year 2021 revenue of between $360 million and $370 million. That range reflects year-over-year growth of 26% to 29%, below the 34% revenue increase delivered in 2020.

Now what

Investors will want to keep their eyes on Guardant Health's launch of Guardant Reveal. It's the first blood-only liquid biopsy test for residual disease and recurrence monitoring of early-stage colorectal cancer and has a seven-day turnaround time. The company also expects to launch its tissue-based comprehensive genomic profiling assay later this year.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Guardant Health, Inc. Stock Quote
Guardant Health, Inc.
GH
$36.77 (5.81%) $2.02

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
330%
 
S&P 500 Returns
115%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 05/23/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.